Clinical trial ELUCIDATE
A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors.
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Exscientia AI Limited |
| EudraCT Identifier | 2023-508227-13-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05985655 |
| Last update |